Christopher Twitty - 23 Apr 2025 Form 3 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
Chief Scientific Officer
Signature
/s/ Kaitlyn Arsenault, as Attorney-in-Fact
Issuer symbol
SKYE
Transactions as of
23 Apr 2025
Net transactions value
$0
Form type
3
Filing time
25 Apr 2025, 16:03:41 UTC
Previous filing
10 Mar 2022
Next filing
09 Feb 2026
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SKYE Common Stock 81,242 23 Apr 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SKYE Stock Option (Right to Buy) 23 Apr 2025 Common Stock 17,004 $3.50 Direct F2
holding SKYE Stock Option (Right to Buy) 23 Apr 2025 Common Stock 75,000 $14.56 Direct F3
holding SKYE Stock Option (Right to Buy) 23 Apr 2025 Common Stock 7,100 $3.50 Direct F4
holding SKYE Stock Option (Right to Buy) 23 Apr 2025 Common Stock 200,000 $5.15 Direct F5
holding SKYE Stock Option (Right to Buy) 23 Apr 2025 Common Stock 150,000 $2.89 Direct F6
holding SKYE Stock Option (Right to Buy) 23 Apr 2025 Common Stock 12,000 $4.25 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes (a) 14,060 restricted stock unit ("RSU") awards that vests upon the company achieving a market capitalization of $500 million or more and (b) 25,000 RSUs that vest upon the achievement of the following performance milestones: (i) 25% vests upon the company achieving a market capitalization of $750 million and a stock price of $20.00 per share, (ii) an additional 25% vests upon the company achieving a market capitalization of $1 billion and a stock price of $25.00 per share, (iii) an additional 25% vests upon the company achieving a market capitalization of $1.25 billion and a stock price of $30.00 per share and (iv) an additional 25% vests if the company achieves a market capitalization of $1.5 billion or greater and a stock price of $35.00 per share.
F2 The stock option vests in equal monthly installments over the four year period beginning on August 24, 2023.
F3 The stock option vests in equal monthly installments over the four year period beginning February 29, 2024.
F4 The stock option vests in equal monthly installments over the four year period beginning August 24, 2023.
F5 The stock option vests in equal monthly installments over the four year period beginning October 28, 2024.
F6 The stock option vests in equal monthly installments over the one year period beginning February 21, 2025.
F7 The stock option vests 25% on December 8, 2023 and 1/48th monthly thereafter.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney